# Aradigm

> Benefits platform enabling sustainable employer access to cell and gene therapies.

## Why it is interesting

Public benefit corporation pooling CGT risk for employers and payors — founded by Will Shrank (ex-Humana, CMS, a16z venture partner) to solve million-dollar therapy affordability.

## Profile

- **Stage:** series-a
- **Status:** private
- **Industries:** healthtech, biotech-life-sciences
- **Coverage:** full
- **Last updated:** 2026-07-24

## Key facts

- Series A (2025): co-led by Frist Cressey and Morgan Health with a16z; Two Sigma Ventures and First Round named in reporting (Endpoints News)
- Seed (2024): a16z led at inception (a16z announcement)
- Model: PBC pooling CGT risk for employer-sponsored health plans (Aradigm site)
- Co-investors not in VCT directory: Frist Cressey Ventures, Morgan Health

## Investors in our directory

- https://venturecapitaltracker.com/fund/andreessen-horowitz
- https://venturecapitaltracker.com/fund/first-round
- https://venturecapitaltracker.com/fund/two-sigma-ventures

## Related articles

- https://venturecapitaltracker.com/2026-a16z-hot-portfolio-companies

---
Source: https://venturecapitaltracker.com/startup/aradigm